Although the available drugs can profoundly alleviate the clinical symptoms in ∼80–90% of the CF population, they inefficiently restore the activity of CFTR mutants harboring nonsense and some splicing mutations, which account for approximately 10% of all mutations in CF (Clinical and Functional Translation of CFTR: http://cftr2.org). The gene discussed is CFTR; the disease is cystic fibrosis.